[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369394-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-369394-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","comprehensive-analysis-of-glycometabolism-related-genes-reveals-plod2-as-a-prognostic-biomarker-and-therapeutic-target-in-gastric-cancer","Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer","","Gastric cancer is a major cause of cancer mortality worldwide, with limited options and poor outcomes, especially in advanced disease. This study examines how glycometabolism-related genes influence tumor progression, immune escape, and therapeutic response. Transcriptomic and clinical data were integrated from TCGA and GEO, and machine learning was used to build a prognostic model. Functional, immune, and pathway analyses identified PLOD2 as the most significant gene.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-analysis-of-glycometabolism-related-genes-reveals-plod2-as-a-prognostic-biomarker-and-therapeutic-target-in-gastric-cancer/369394/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-analysis-of-glycometabolism-related-genes-reveals-plod2-as-a-prognostic-biomarker-and-therapeutic-target-in-gastric-cancer/369394.png","ImageObject",300,407,{"name":42,"@type":43},"Rhys","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What question does the study address about glycometabolism in gastric cancer?","Question",{"text":62,"@type":63},"The study evaluates the roles of glycometabolism-related genes in gastric cancer and how they relate to prognosis and therapeutic implications, focusing on their contribution to tumor progression and immune escape.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How was the prognostic model constructed and validated?",{"text":67,"@type":63},"Transcriptomic and clinical data from gastric cancer patients were retrieved from TCGA and GEO, and glycometabolism-related genes were analyzed with machine learning to build and validate a four-gene prognostic model.",{"name":69,"@type":60,"acceptedAnswer":70},"Why is PLOD2 highlighted in the findings?",{"text":71,"@type":63},"PLOD2 showed the highest prognostic significance, correlated with tumor progression and poor survival, promoted glycolysis via the PI3K/AKT/mTOR pathway, and was linked to an immunosuppressive tumor microenvironment.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},369394,1792235261,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Ye etal. BMCGastroenterology (2025) 25:256 [https://doi.org/10.1186/s12876-025-03878-z](https://doi.org/10.1186/s12876-025-03878-z)  \nBMC Gastroenterology  \n RESEARCH Open Access  \nComprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer  \nWanchun Ye1†, Xiaolei Zhang2†, Zhongjie Tang1, Yufeng Hu1, Yuanliang Zheng1 andYuping Yuan1*  \nAbstract  \nBackground Gastric cancer (GC) is one of the leading causes of cancer-related mortality worldwide, with limited therapeutic options and a poor prognosis, particularly in advanced stages. Glycometabolism, a hallmark of cancer, plays a critical role in tumor progression, immune evasion, and response to therapy. However, the specific roles of glycometabolism-related genes and their prognostic and therapeutic implications in GC remain inadequately understood.  \nMethods Transcriptomic and clinical data from GC patients were retrieved from TCGA and GEO databases. Glycometabolism-related genes were identified and analyzed using machine learning algorithms to construct a prognostic model. Functional assays, immune profiling, and pathway enrichment analyses were performed to explore the roles of these genes in tumor progression, immune-modulatory effects, and drug resistance. PLOD2, the gene with the highest prognostic significance, was further investigated to uncover its underlying regulatory mechanisms, roles in immune modulation, and contribution to therapeutic resistance.  \nResults A glycometabolism-related prognostic model consisting of four genes (PLOD2, CHSY3, SLC2A3 and SLC5A1) was developed and validated, effectively stratifying GC patients into high-and low-risk subgroups with distinct survival outcomes. Among these, PLOD2 emerged as the most significant gene, exhibiting strong associations with tumor progression and poor survival. Functional analyses revealed that PLOD2 promotes glycolysis and tumor progression through activation of the PI3K/AKT/mTOR pathway. Immune profiling revealed that PLOD2 overexpression is associated with an immunosuppressive tumor microenvironment, characterized by increased M2 macrophage infiltration and reduced immune activity. Moreover, treatment with rapamycin, an mTOR inhibitor, significantly suppressed PLOD2-mediated proliferation and anchorage-independent growth in GC cells, highlighting the central role of the PI3K/AKT/mTOR pathway in PLOD2-driven oncogenic behaviors.  \nConclusions This study identifies PLOD2 as a key prognostic biomarker and therapeutic target in gastric cancer. As a central component in a glycometabolism-related model, PLOD2 promotes glycolysis, tumor progression, and immune evasion via the PI3K/AKT/mTOR pathway. The model effectively stratifies patient risk, offering  \n†Wanchun Ye and Xiaolei Zhang have contributed equally to this work.  \n*Correspondence: Yuping Yuan[ypyuan89@126.com](ypyuan89@126.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [htt","cbCainspg64kyuzG","https://ap.wps.com/l/cbCainspg64kyuzG","pdf",6060200,17,"English","# Abstract\n# Introduction\n## Gastric cancer burden and prognosis challenges\n## Hypoxia, metabolic reprogramming, and glycometabolism context","[{\"question\":\"What question does the study address about glycometabolism in gastric cancer?\",\"answer\":\"The study evaluates the roles of glycometabolism-related genes in gastric cancer and how they relate to prognosis and therapeutic implications, focusing on their contribution to tumor progression and immune escape.\"},{\"question\":\"How was the prognostic model constructed and validated?\",\"answer\":\"Transcriptomic and clinical data from gastric cancer patients were retrieved from TCGA and GEO, and glycometabolism-related genes were analyzed with machine learning to build and validate a four-gene prognostic model.\"},{\"question\":\"Why is PLOD2 highlighted in the findings?\",\"answer\":\"PLOD2 showed the highest prognostic significance, correlated with tumor progression and poor survival, promoted glycolysis via the PI3K/AKT/mTOR pathway, and was linked to an immunosuppressive tumor microenvironment.\"}]","Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer | PDF",1790182420,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88a9d4f41e6ba9ceee2825affe70cc93.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b02234e5983a17f82d2ab133cf5eca29.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/050e8b2395f637ba5a44e184c19b243c.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67d985ea6615bd39c83a3ebe4b054ada.webp",980,1301]